Denator AB today announced that it has completed the fourth round of financing, raising a total of 15 million SEK. The financing has been subscribed by a strong group of investors that include the existing investors T-bolaget AB, Wikow Ventures AB & Servisen Holding AB as well as existing private shareholders but also new financial investors such as the SGP Group (Svenska Garantiprodukter AB).

The proceeds, which are expected to be sufficient to reach positive cash flow, will be used to continue building Denator’s position in the global protein research market. The funds will be used to further develop the company’s product line and research activities, and to expand its sales and marketing activities.

Olof Sköld, CEO at Denator says: “We are pleased to have secured this sizeable financing round. The strong level of commitment from our shareholders will enable the company to continue its expansion. This financing round underlines the significant commercial opportunity the company has through applying its stabilization technology to several fields within the Life Science market. Our technology represents a significant advance over other approaches and this funding will support the next step in the company’s development.”

Henrik Wingstrand, CEO of T-bolaget AB says: ”Denator is a core holding for us and we are happy to continue to support this very promising company.”

Denator’s first commercial system for instant tissue stabilization was launched at the HUPO meeting in Amsterdam in August, 2008.

About Denator

Denator intends to become the leading supplier of products that stabilize biological tissues and fluids from the moment of sampling. Stabilization and standardization of sampling processes upstream significantly enhances the quality of data obtained from analytical techniques used downstream. In proteomic and peptidomic investigations, enhanced data quality increases the reliability of data interpretation and can reveal novel proteins and peptides that would be lost or undetectable when using conventional preparation techniques. Based upon the company’s proprietary heat-inactivation technology platform, Denator is developing solutions that enable scientists to stop sample degradation instantly and maintain the stability of sample components throughout the analytical workflow. Established in 2004, Denator is headquartered at the Biotech Center in Gothenburg, Sweden. For more information visit: www.denator.com